Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
Musso G, Gambino R, Cassader M, Paschetta E
BMJ. 2019;365:l1328
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Musso G, Gambino R, Cassader M, Paschetta E
BMJ. 2019;365:l1328
Leggi
Nicholson L, Ramu J, Chan EW, et al.
JAMA Ophthalmol. Published online, 11 April 2019.
Leggi
Muñoz-Velandia O, Guyatt G, Devji T, et al.
Diabetes Technol Ther. 2019;21(4):183-200
Leggi
Whelton SP, Dardari Z, Handy Marshall C, et al.
Am J Cardiol. 2019;123(9):1429-34
Leggi
Zahir SF, Griffin A, Veerman JL, et al.
Diabetologia. 2019;62:754-8
Leggi
He X, Rebholz CM, Daya N, et al.
Diabetologia. 2019;62:770-8
Leggi
Yeung CHC, Au Yeung SL, Fong SSM, et al.
Diabetologia. 2019;62:789-99
Leggi
Boughton CK, Bally L, Martignoni F, et al.
The Lancet Diabetes &Endocrinology. Pub. online 29 March 2019
Leggi
Gillard P, Charleer S, Mathieu C
The Lancet Diabetes & Endocrinology. Pub online 29 March 2019
Leggi
Schmidt MI, Bracco PA, Yudkin JS, et al.
Lancet Diabetes Endocrinol. 2019;7(4):267-7
Leggi